On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
Browsing: Kidney
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered…
Author: Dr. Regina Barragan-Carillo, City of Hope Overview: At ASCO 2024, Dr. Regina Barragan-Carillo from City of Hope Cancer Center…
… Dr. Sumanta (Monty) Kumar Pal, M.D., FASCO highlights some of the top data and presentations being presented in kidney and…
Presented By: Dalia Kaakour, MD – University of California, Irvine Date: Aug 12, 2023 In the realm of oncology and…
Pembrolizumab plus Lenvatinib, individually known for their robust anti-cancer mechanisms, when combined, show significant promise in treating advanced renal cell…
FOTIVDA is Aveo’s marketed product for treating advanced renal cell carcinoma, primarily used as a later line agent in the…
Corina Dutcus, MD from Eisai Inc provided a summary of the findings from a clinical trial evaluating the combination of…
CD70: How Does ALLO-316 Eliminate or Destroy Malignancies in the TRAVERSE Trial? Samer Srour, MB ChB, MS By Samer Srour,…
Renal Cell Carcinoma Trials: Guidelines and Eligibility According to ASCO-FCR: An Overview of RCC Trials Anna Odell by Anna Odell,…
Renal Cell Carcinoma Trials: ASCO-FCR Guidelines for Renal Cell Carcinoma Trial Eligibility Ishann Sehgal by Ishann Sehgal, City of Hope…
Belzutifan and other Novel Therapies in Genitourinary Oncology 2023 By Rana McKay, MD – University of California San Diego We’re…
CHECKMATE-914 Phase 3 Dr. Brian Rini, MD [2022] CHECKMATE-914 Trial The purpose of this study is to determine if the…
COSMIC-313 Phase 3 Kidney Cancer Trial [2022] COSMIC-313 Kidney Cancer Trial I’m going to talk today about COSMIC-313 ( Ipi/Nivo…
CHECKMATE-914 Phase 3 Kidney Cancer Trial [2022] CHECKMATE-914 Trial I’m going to talk to you today about CHECKMATE-914 clinical trial,…
Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously received…
Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO…
Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO…
Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair…
Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair…
Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU…
Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU…
Dharmesh Gopalakrishnan, MD, a Hematology-Oncology Fellow at Roswell Park speaks about the ASCO 2021 Abstract – Immune checkpoint inhibitors (ICI)…
Brian Rini, MD, Professor of Medicine from Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center speaks about Pembrolizumab (pembro) plus axitinib…
Brian Rini, MD Professor of Medicine from Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center speaks about AVEO Oncology Announces U.S.…
Xiaoqiang Wang, MD, Ph.D., MB (ASCP) from the City of Hope speaks about White button mushrooms could slow progression of…
Bradley McGregor, MD of the Dana-Farber Cancer Institute speaks about Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.Link to…
Zeynep Busra Zengin, MD, a postdoctoral fellow at the City of Hope, a comprehensive cancer center discusses the ASCO GU…
Sumanta (Monty) K. Pal, MD of the City of Hope speaks about A randomized, multi-arm comparison of targeted therapies for…
Sumanta Pal, M.D., co-director of the Kidney Cancer Program at City of Hope ESMO Virtual Congress 2020: COSMIC-021, Cabozantinib in…
Andrew Lachlan Schmidt, M.B., B.S. of Dana-Farber Cancer Institute speaks about Novel Therapeutic Approaches and the Evolution of Drug Development…
Matthew Tucker, Clinical Fellow at Vanderbilt University Medical Center discusses Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma.Quick SummaryImmunotherapy-based…
Maxime Meylan, PhD of the Centre de Recherche des Cordeliers explains the ESMO Virtual Congress 2020: Clear Cell Renal Cell…
Andrea B. Apolo, MD of NIH National Cancer Institute speaks about the ESMO 2020 abstract New First-Line Treatment Option For…
Rana R. McKay, MD UC SD Health discusses ASCO 2020 abstract entitled Optimized management of nivolumab (Nivo) and ipilimumab (Ipi)…
Ramaprasad Srinivasan, M.D., Ph.D. – NIH National Cancer Institute Results from a phase II study of bevacizumab and erlotinib in…
David A. Braun, MD, PhD from Dana Farber discusses an ASCO 2020 abstract entitled Immunogenomic characterization of advanced clear cell…
Eric Jonasch, MD @MDAndersonNews #ASCO2020 gives an overview of the Phase II study of the oral HIF-2α inhibitor MK-6482 for…
Elizabeth Plimack, MD @FoxChaseCancer gives an updated analysis of KEYNOTE-426 at ASCO 2020 Pembrolizumab plus axitinib versus sunitinib as first-line…
Tanya Dorff, MD Associate Clinical Professor of MedicineHead of Genitourinary Cancer Program City of Hope discusses Genitourinary Cancers:Evolving Practices and…
Hans Hammers, MD of UT Southwestern Medical Center discusses the role of radiation in kidney cancer at the KCA 2019.
Meredith M. Regan,1 Michael B. Atkins,2 Thomas Powles,3 Lillian Werner,4 Charlene Mantia,5 Shuo Yang,6 Jennifer L. Johansen,6 Sumati Rao,6 Kyna…
Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro…
Nicholas Vogelzang, MD of Comprehensive Cancer Centers discusses his moderation of modern imaging technology.
Nicholas Vogelzang, MD of Comprehensive Cancer Centers discusses his moderation of modern imaging technology.
Ulka Vaishampayan, MD of @karmanoscancer explains her moderation of management for clinical cases in kidney cancer.
James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer…
Matt Campbell MD Assistant Professor GU Medical Oncology discusses The Argument for Front Line TKI based treatment for non-clear cell…
Viraj Master MD PhD FACS Professor Fray F. Marshall Chair in Urological Research Department of Urology Director of Integrative Oncology…